As an non-medical observer the editorial was unprecedented, and gave me no assurance the drug had proven to be even mediocre. Further, I would
in my opinion only, advance the notion, that if I was credentialed to see such patients with Alzheimer's, knowledge of an FDA approved "something" drug would finally stop dead in its tracks, the dread I would have explaining to the patient and family that I could not lift a finger to slow the inevitable catastrophic circumstance.. Free of such a burden, I may be less susceptible to forming a bias unfavorable to the discussed drug approval by the FDA, which finally authorizes me to claim to the patient and family I have some sort of remedy to slow the impending rapid brain functioning deterioration.
I would be eager to hear a debate regarding this affair and proposals to remedy the merits of this disputable drug, by other "worthy" leading edge drug trial scholars, published in Nature or similar esteemed publications.
Market Data 
Markets 
AI
